Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin backgroundJennifer G. Robinson,Michel Farnier,John J. P. Kastelein,Eli M. Roth,M.-R. Taskinen,Helen M. Colhoun, A. Brunet,A.T. DiCioccio, G. Lecorps,Robert Pordy,Marie T. Baccara-Dinet,Christopher P. CannonATHEROSCLEROSIS(2016)引用 1|浏览9暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要